Cord Blood Registry (CBR), currently operating under the parent company Celularity Inc. (Nasdaq: CELU), remains a central entity in the private cord blood banking industry. Established in 1992, the company specializes in the collection and cryopreservation of hematopoietic stem cells derived from umbilical cord blood. These cells are stored for potential future medical use, primarily in the treatment of specific blood cancers and immune disorders, as outlined in official company regulatory filings.
Operational History and Market Position
Cord Blood Registry was the first private cord blood bank to begin operations in the United States. Following its founding in 1992, the company expanded its services to include the processing and storage of reproductive tissue, including cord tissue, which contains mesenchymal stem cells.
In 2018, the company was acquired by Celularity Inc., a clinical-stage biotechnology firm focused on allogeneic cellular therapies. According to Celularity’s official investor relations disclosures, the integration of CBR provided the company with an established infrastructure for tissue collection and long-term storage, which supports its broader research into placenta-derived cell therapies.
Clinical Utility of Stored Stem Cells
The primary medical justification for cord blood banking is the presence of hematopoietic stem cells (HSCs). These cells possess the capacity to differentiate into various blood cell types, including red blood cells, white blood cells, and platelets.
According to the National Marrow Donor Program (Be The Match), cord blood units are used in hematopoietic cell transplantation to treat over 80 diseases, including leukemia, lymphoma, and various inherited metabolic disorders. While the majority of successful cord blood transplants utilize units from public banks—where inventory is available to any matched patient—private banking is marketed to families as a form of biological insurance for the donor or their immediate family members.
Current Regulatory and Financial Context
As a component of Celularity Inc., Cord Blood Registry’s financial performance is reported within the parent company’s quarterly and annual filings with the U.S. Securities and Exchange Commission (SEC). Celularity, which trades on the Nasdaq exchange under the ticker symbol CELU, utilizes the revenue generated from its banking operations to help fund its ongoing clinical trials for cancer and degenerative disease treatments.
Investors and stakeholders can monitor the company’s performance via SEC EDGAR filings, which detail the operational costs associated with maintaining cryopreservation facilities and the regulatory compliance standards required by the FDA for human tissue banking.
Frequently Asked Questions
What is the difference between private and public cord blood banks?
Public banks accept cord blood donations for use by any patient in need of a transplant. Private banks, such as CBR, store cord blood exclusively for the use of the donor or the donor’s family for a fee.
Are stem cells from cord blood guaranteed to cure diseases?
No. While cord blood is an established treatment for specific blood-related conditions, there is no guarantee that a stored unit will be used or that it will be effective for every potential medical application.
What happens to stored samples if a company undergoes financial changes?
When private banks are acquired, storage contracts typically remain in effect. Celularity Inc. maintains the storage facilities and obligations previously held by Cord Blood Registry, subject to the terms of the original service agreements signed by clients.
Related reading